AB Science S.A. (Euronext:AB) was up €0.29 to €11.32 on Friday after EMA's CHMP reiterated its recommendation against conditional approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic cancer in combination with gemcitabine. The company said it plans to resubmit the MAA and seek full approval with data from a planned Phase III confirmatory trial; data are expected in 2H17.
AB Science was off €0.15 last week.
Active Biotech AB (SSE:ACTI) was off SEK0.20 to SEK35.50 on Friday after EMA's CHMP reiterated a recommendation against approval of Nerventra laquinimod to treat relapsing-remitting multiple sclerosis (RRMS). Partner Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), which was up $1.11 to $51.77 on Friday, said it plans to continue the Phase III CONCERTO trial of Nerventra in RRMS.
Last week, Teva gained $1.96. Active Biotech gained SEK0.10.